Search

ESMO18: NOVARTIS PI3K COMBO THERAPY BOOSTS SURVIVAL IN SUBSET OF BREAST CANCER PATIENTS

Novartis has come out with data at this year's European cancer congress ESMO with positive results from a phase 3 looking at its investigational...

Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

 
 
 
Cancer-therapy provider Endocyte spikes 50% after Novartis agrees to buy it for $2.1 billion

CANCER-THERAPY PROVIDER ENDOCYTE SPIKES 50% AFTER NOVARTIS AGREES TO BUY IT FOR $2.1 BILLION

Novartis , the Swiss drug maker, has agreed to buy the US cancer-treatment provider Endocyte , for $2.1 billion. Under the agreement,...

What It's Really Like To Live With Metastatic Breast Cancer

WHAT IT'S REALLY LIKE TO LIVE WITH METASTATIC BREAST CANCER

Branded - Novartis: Cancer Can Kiss This Episode 1 Breast cancer awareness is so much more than pink ribbons, painted bras, and feather...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

NOVARTIS-BACKED CELL THERAPY STARTUP GAMIDA FILES FOR IPO

Gamida Cell has filed to raise $69 million in a Nasdaq IPO. The Novartis-backed cell therapy player wants the money to wrap up a phase...

 
 
 
Drugmakers are using an unusual tactic to compete in a new class of medication - giving it away for free

DRUGMAKERS ARE USING AN UNUSUAL TACTIC TO COMPETE IN A NEW CLASS OF MEDICATION - GIVING IT AWAY FOR FREE

Since May, the FDA has approved three new drugs in a new class of preventive migraine medication: Aimovig, made by Amgen and Novartis;...

Bio Roundup: Amarin's Stunner, Lung Cancer News, Data Dumps & More

BIO ROUNDUP: AMARIN'S STUNNER, LUNG CANCER NEWS, DATA DUMPS & MORE

Six years ago, a biotech called Amarin won FDA approval of a prescription fish-oil pill, Vascepa, because it could lower triglycerides,...

 
 
 

SALES SPECIALIST- MS - SAN DIEGO CA - NOVARTIS - SAN DIEGO, CA

2 years was in a specialty pharmaceutical /biotech sales within the last 5 years. Interpersonal communication, organization & prioritization,...

 
 
 
In-house CAR-T manufacturing preferable to outsourcing, execs say

IN-HOUSE CAR-T MANUFACTURING PREFERABLE TO OUTSOURCING, EXECS SAY

Keeping manufacturing close to home allows for greater flexibility, lower long-term costs and building up native manufacturing capability,...

Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
Subject CAR-Ts to price competition or randomized trials to ensure even coverage, expert says

SUBJECT CAR-TS TO PRICE COMPETITION OR RANDOMIZED TRIALS TO ENSURE EVEN COVERAGE, EXPERT SAYS

CMS could run trials of CAR-Ts in lymphoma if unsure of their similarity on benefit to patients and ancillary service costs, Dr. Peter...

 
 
 
 
 
 
Bio Roundup: Alnylam's Moment, Read on Rebates, Skinny Plans & More

BIO ROUNDUP: ALNYLAM'S MOMENT, READ ON REBATES, SKINNY PLANS & MORE

Millions of people might be on vacation as we hit the dog days, but drug makers and politicians aren't taking a break from the gamesmanship...

 
 
 
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More

BIO ROUNDUP: DRUG PRICES, CRISPR CAVEATS, RUBIUS IPO POP & MORE

After nearly two years of all smoke, no fire around President Trump's promise to curtail drug prices, there's finally some glimmer...

Pharmaceutical companies are backing away from a growing threat that could kill 10 million people a year by 2050

PHARMACEUTICAL COMPANIES ARE BACKING AWAY FROM A GROWING THREAT THAT COULD KILL 10 MILLION PEOPLE A YEAR BY 2050

Novartis in July became the latest pharmaceutical company to shut down its antibiotics research projects. The move comes as FDA commissioner...